As of September 30, 2026, Takeda Pharmaceutical Company Limited carries a market capitalization of 58.73B, placing it among publicly traded companies globally. Its enterprise value stands at 84.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 58.73B |
| Enterprise Value | 84.93B |
Takeda Pharmaceutical Company Limited's next confirmed earnings release is scheduled for January 28, 2027.
| Earnings Date | 1/28/2027 |
As of September 30, 2026, Takeda Pharmaceutical Company Limited has 3.23B shares outstanding.
| Shares Outstanding | 3.23B |
As of September 30, 2026, Takeda Pharmaceutical Company Limited trades at a trailing price-to-earnings ratio of 222.69. The price-to-sales ratio is 1.94, and the price-to-book ratio stands at 1.25.
| PE Ratio | 222.69 |
| PS Ratio | 1.94 |
| PB Ratio | 1.25 |
| P/TBV Ratio | -6.22 |
| P/FCF Ratio | 21.18 |
| P/OCF Ratio | 10.33 |
As of September 30, 2026, Takeda Pharmaceutical Company Limited trades at an EV/EBITDA multiple of 15.88 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.85 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 83.84 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 84.93B versus a market cap of 58.73B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 2.85 |
| EV / EBITDA | 15.88 |
| EV / EBIT | 83.84 |
As of September 30, 2026, Takeda Pharmaceutical Company Limited maintains a current ratio of 1.15, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.69, indicating elevated leverage, while an interest coverage ratio of 9.89 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.15 |
| Quick Ratio | 0.52 |
| Debt / Equity | 61.69 |
| Debt / EBITDA | 5.44 |
| Interest Coverage | 9.89 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Company Limited posted a return on equity (ROE) of 0.56, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.27, measuring how efficiently the asset base is converted into earnings. The company generates approximately 632,786.97 in revenue per employee across its workforce of 47,135.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.17 indicates how many times Takeda Pharmaceutical Company Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 0.56 |
| Return on Assets (ROA) | 0.27 |
| Revenue Per Employee | 632,786.97 |
| Employee Count | 47,135.50 |
| Inventory Turnover | 1.17 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Company Limited recorded an income tax benefit of -276.53M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -15.70M and 259.26M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -276.53M |
As of the close on November 16, 2026, Takeda Pharmaceutical Company Limited's stock has gained approximately 51.08% over the past 52 weeks. The 50-day moving average sits at 19.46, while the 200-day moving average is 17.80.
| 52-Week Price Change | 51.08% |
| 50-Day Moving Average | 19.46 |
| 200-Day Moving Average | 17.80 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Company Limited generated 29.83B in revenue and converted that into 259.26M in net income, yielding earnings per share of 0.08. EBITDA reached 5.35B, while operating income came in at 4.43B.
| Revenue | 29.83B |
| Gross Profit | 19.62B |
| Operating Income | 4.43B |
| Pretax Income | -15.70M |
| Net Income | 259.26M |
| EBITDA | 5.35B |
| EBIT | 1.01B |
| Earnings Per Share (EPS) | 0.08 |
As of September 30, 2026, Takeda Pharmaceutical Company Limited holds 2.89B in cash and equivalents against 29.08B in total debt, resulting in a net debt position of 26.42B. Total book value stands at 47.13B, with working capital of 2.50B providing operational flexibility.
| Cash & Cash Equivalents | 2.89B |
| Total Debt | 29.08B |
| Net Debt | 26.42B |
| Equity (Book Value) | 47.13B |
| Book Value Per Share | 14.60 |
| Working Capital | 2.50B |
Takeda Pharmaceutical Company Limited produced 5.59B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -2.83B in capital expenditures, free cash flow totaled 2.76B - equivalent to 0.87 per share.
| Operating Cash Flow | 5.59B |
| Capital Expenditures | -2.83B |
| Free Cash Flow | 2.76B |
| FCF Per Share | 0.87 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Company Limited posted a gross margin of 65.79, reflecting its pricing power and cost economics. The operating margin of 14.86 and net profit margin of 0.87 provide insight into operational efficiency.
| Gross Margin | 65.79 |
| Operating Margin | 14.86 |
| Pretax Margin | -0.05 |
| Profit Margin | 0.87 |
| EBITDA Margin | 17.93 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Company Limited paid dividends of 0.63 per share. The dividend payout ratio of 764.63 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.72, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Takeda Pharmaceutical Company Limited shareholders.
| Dividend Per Share | 0.63 |
| Payout Ratio | 764.63 |
| Shareholder Yield | 8.24 |
| FCF Yield | 4.72 |
As of September 30, 2026, Takeda Pharmaceutical Company Limited has an Altman Z-Score of 2.07, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.07 |
Already premium?